Search results
Results from the WOW.Com Content Network
Lenalidomide, sold under the brand name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (MDS). [8] For multiple myeloma, it is a first line treatment, and is given with dexamethasone . [ 8 ]
The thalidomide molecule is a synthetic derivative of glutamic acid and consists of a glutarimide ring and a phthaloyl ring (Figure 5). [15] [16] Its IUPAC name is 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione and it has one chiral center [15] After thalidomide's selective inhibition of TNF-α had been reported, a renewed effort was put in thalidomide's clinical development.
A bottle of Revlimid and pills are seen at the Huntsman Cancer Institute at the University of Utah in Salt Lake City, Utah, U.S. July 22, 2022. ... Drugs administered by doctors such as ...
Presently, however, such therapy is FDA-approved only for patients in later stages of the disease and is available only at certain medical centers. [98] An upcoming therapy that also leverages T-cell immune response is the class of drugs termed bispecific T-cell engagers (BITE), or sometimes simply bispecific antibodies.
In the European Union, pomalidomide, in combination with bortezomib and dexamethasone, is indicated in the treatment of adults with multiple myeloma who have received at least one prior treatment regimen including lenalidomide; [8] and in combination with dexamethasone is indicated in the treatment of adults with relapsed and refractory multiple myeloma who have received at least two prior ...
Experts have hailed the “beginning of the end” in the search for effective Alzheimer’s treatments after a new drug reduced memory decline among patients with early stages of the disease.
Psychological therapies for dementia are starting to gain some momentum. [ when? ] Improved clinical assessment in early stages of Alzheimer's disease and other forms of dementia , increased cognitive stimulation of the elderly, and the prescription of drugs to slow cognitive decline have resulted in increased detection in the early stages.
Simulated presence therapy (SPT) is an emotion-oriented non-pharmacological intervention for people with dementia developed by P. Woods and J. Ashley in 1995. SPT was created as part of a study conducted in a nursing home where 17 individuals with the disease listened to a recording of a caregiver over a stereo. [1]